Cargando…
Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma
Glioblastoma is the most aggressive primary brain tumor in humans and is virtually incurable with conventional therapies. Chimeric antigen receptor (CAR) T cell therapy targeting the glioblastoma antigen EphA2 is an attractive approach to improve outcomes because EphA2 is expressed highly in gliobla...
Autores principales: | Yi, Zhongzhen, Prinzing, Brooke L., Cao, Felicia, Gottschalk, Stephen, Krenciute, Giedre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852415/ https://www.ncbi.nlm.nih.gov/pubmed/29552579 http://dx.doi.org/10.1016/j.omtm.2018.01.009 |
Ejemplares similares
-
Hypoxia-inducible CAR expression: An answer to the on-target/off-tumor dilemma?
por: Prinzing, Brooke, et al.
Publicado: (2021) -
MyD88/CD40 signaling retains CAR T cells in a less differentiated state
por: Prinzing, Brooke, et al.
Publicado: (2020) -
Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma
por: Petersen, Christopher T., et al.
Publicado: (2019) -
IMMU-01. Combining CD28 and 4-1BB costimulationin trans enhances the anti-glioma efficacy and persistence of B7-H3 CAR T cells in immune-competent brain tumor models
por: Haydar, Dalia, et al.
Publicado: (2022) -
IMMU-05. B7-H3-SPECIFIC CAR T CELLS HAVE POTENT ANTI-TUMOR ACTIVITY IN THE GL261 IMMUNE-COMPETENT MURINE BRAIN TUMOR MODEL
por: Haydar, Dalia, et al.
Publicado: (2020)